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Abstract
Background: The Philippines has been one of the most affected COVID-19 countries in the Western Pacific region,
but there are limited data on COVID-19-related mortality and associated factors from this setting. We aimed to
describe the epidemiological and clinical characteristics and associations with mortality among COVID-19-confirmed
individuals admitted to an infectious diseases referral hospital in Metro Manila.
Main text: This was a single-centre retrospective analysis including the first 500 laboratory-confirmed COVID-19
individuals admitted to San Lazaro Hospital, Metro Manila, Philippines, from January to October 2020. We extracted
clinical data and examined epidemiological and clinical characteristics and factors associated with in-hospital
mortality. Of the 500 individuals, 133 (26.6%) were healthcare workers (HCW) and 367 (73.4%) were non-HCW, with
HCW more likely presenting with milder symptoms. Non-HCW admissions were more likely to have at least one
underlying disease (51.6% vs. 40.0%; p = 0.002), with hypertension (35.4%), diabetes (17.4%), and tuberculosis (8.2%)
being the most common. Sixty-one (12.2%) died, comprising 1 HCW and 60 non-HCW (0.7% vs. 16.3%; p < 0.001).
Among the non-HCW, no death occurred for the 0–10 years age group, but deaths were recorded across all other
age groups. Compared to those who recovered, individuals who died were more likely to be older (p < 0.001), male
(p = 0.015), report difficulty of breathing (p < 0.001), be HIV positive (p = 0.008), be intubated (p < 0.001),
categorised as severe or critical (p < 0.001), have a shorter mean hospital stay (p < 0.001), or have an additional
diagnosis of pneumonia (p < 0.001) or ARDS (p < 0.001).
Conclusion: Our analysis reflected significant differences in characteristics, symptomatology, and outcomes
between healthcare and non-healthcare workers. Despite the unique mix of cohorts, our results support the
country’s national guideline on COVID-19 vaccination which prioritises healthcare workers, the elderly, and people
with comorbidities and immunodeficiency states.
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Background
The COVID-19 pandemic caused by the severe acute re-
spiratory syndrome coronavirus-2 (SARS-CoV-2) is now
in its second year [1, 2]. The Philippines, already with a
high burden of infectious disease [3], has been one of
the hardest hit countries in the Western Pacific region
[4]. As of April 2021, the densely populated National
Capital Region (NCR) has been the epicentre of COVID-
19, contributing to almost half the cases in the
Philippines [5, 6]. Significant progress has been made in
a short period of time in terms of understanding the
virus’ pathogenesis, transmission, and symptomatology
[7, 8]. Therapeutic modalities have been evaluated and
vaccines developed [9–11]. While initial doses of the
COVID-19 vaccine have been given to priority popula-
tions (healthcare workers, the elderly, and those with co-
morbidities) in the Philippines since March 2021 [9, 10],
only 739,000 individuals had received at least one dose
of vaccine, comprising < 1% of the total population [9].
Hospitals in the NCR are still experiencing a heavy in-
flux of patients presenting with severe to critical symp-
toms of COVID-19. One way to help alleviate the
burden in the hospitals is to further identify those who
would benefit most from the available COVID-19 vac-
cines. While numerous publications are available for
Western and high-income settings, to date, there are still
limited and underrepresented data among Filipinos and
Asians in low-resource settings.
We previously reported an analysis of the first 100 in-
dividuals with suspected COVID-19 admitted to San
Lazaro Hospital (SLH), a tertiary infectious diseases hos-
pital in Metro Manila, during the first months of the
pandemic [11]. Being the national infectious disease re-
ferral centre in the country, SLH caters mostly to pa-
tients with communicable diseases. When the pandemic
started, adjustments in the admission policy were made
to provide care to COVID-19 patients, particularly prior-
itising healthcare workers serving as frontliners in the
fight against the disease. The policy for admission has
changed over time, with subsequent revisions in the cri-
teria for admission (i.e. cases with mild symptoms are
isolated at home or in an isolation facility and not ad-
mitted to a hospital) in order to prioritise those with
more severe presentations. In this follow-up paper, we
aim to describe the epidemiological and clinical charac-
teristics and associations with mortality among the first
500 laboratory-confirmed COVID-19 inpatients from
the same hospital, with a view to identifying individuals
most at risk who could be prioritised for vaccination.
Main text
We conducted a secondary analysis of the first 500
laboratory-confirmed COVID-19 inpatients at SLH, from
January 25, 2020, to October 24, 2020. Anonymised data
on confirmed and suspected cases within the hospital
from COVID-19 case investigation forms (CIF) were pro-
vided by the SLH Epidemiology Department (SLH-ED).
We limited our analysis to individuals with complete data
on case classification and patient outcome. Clinical status
(asymptomatic, mild, moderate, severe) was assessed ac-
cording to the Philippine Department of Health’s Interim
Guidelines on the COVID-19 Disease Severity Classifica-
tion and Management [12]. Available laboratory data on
cycle threshold (Ct) value was collected from the hospital’s
laboratory department. The Philippines’ Department of
Health (DOH) defines a “confirmed case” of COVID-19 as
“any individual, irrespective of the presence or absence of
clinical signs and symptoms, who is laboratory-confirmed
for COVID-19 in a test conducted at the national or sub-
national reference laboratory, and/or officially accredited
laboratory testing facility”. For the purpose of this analysis,
we included individuals categorised in the CIF as con-
firmed cases of COVID-19. We clarified any unclear infor-
mation in the dataset with the staff of the SLH-ED. We
analysed the descriptive statistics of cases, deaths, and re-
coveries by socio-demographics and clinical presentation.
We used proportions and percentages to describe the
characteristics of the study population. Continuous data
were described as means (standard deviation (SD)) if the
data was normally distributed; otherwise, medians (inter-
quartile range) were used. We calculated time in days
from the onset of symptoms to hospital admission, and
length of hospitalisation until death or discharge. Cat-
egorical variables were analysed using χ2 testing. Ana-
lysis of associations with mortality was restricted to
non-healthcare workers, given that all the deaths
apart from one occurred in this group. Stata IC 16.1
was used for all analyses. The study was approved by
the SLH research ethics and review unit (Ref: SLH-
RERU-2020-022-I) and the School of Tropical Medi-
cine and Global Health, Nagasaki University Ethical
Committee (NU_TMGH_2020_119_1).
Table 1 presents the epidemiological and clinical
characteristics of the 500 individuals included in the
analysis, comparing 133 (26.6%) HCW and 367 (73.4%)
non-HCW. Most were aged over 20 with a median age
of 48 years (IQR 34–61). HCW tended to be younger (p
< 0.001). All 16 individuals aged under 20 were non-
HCW. Just over half were males (55.8%), similar for both
groups. All (99.6%) were Filipino nationals apart from
two individuals from China. The majority (73.0%) could
not identify a possible exposure to COVID-19; however,
HCW were more likely to report risk of exposure in the
workplace (p < 0.001). Non-HCW were more likely to
have at least one underlying disease (55.9% vs. 40.0%; p
= 0.002), with hypertension (38.1%), diabetes (20.2%),
and tuberculosis (10.1%) being the most common. The
predominant symptoms among the admitted cases were
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Table 1 Epidemiologic and clinical characteristics of healthcare and non-healthcare workers COVID-19 inpatients in San Lazaro
Hospital, January 2020 to October 2020
Characteristics Total (n = 500) HCW cases (n = 133) non-HCW (n = 367) p-value
Age (years)
Mean (SD) 48 (17) 41 (11.5) 51 (18) < 0.001
Median (IQR) 48 (34–61) 40 (31–50) 53 (38–64)
Age group (years)
0–10 years old 7 (1.4) – 7 (1.9) < 0.001
11–20 years old 9 (1.8) – 9 (2.4)
21–40 years old 158 (31.6) 67 (50.4) 91 (24.8)
41–60 years old 195 (39.0) 58 (43.6) 137 (37.3)
61–80 years old 115 (23.0) 8 (6.0) 107 (29.2)
80+ years old 16 (3.2) – 16 (4.4)
Sex
Female 221 (44.2) 63 (47.4) 158 (43.0) 0.390
Male 279 (55.8) 70 (52.6) 209 (57.0)
Nationality
Filipino 498 (99.6) 133 (100.0) 365 (99.5) 1.000
Chinese 2 (0.4) – 2 (0.5)
Exposure history
International travel history within 14 days prior to admission 9 (1.8) 0 9 (2.4) < 0.001
Exposed to a confirmed case 21 (4.2) 10 (7.5) 11 (3.0)
Risk of exposure in workplace 105 (21.0) 96 (72.2) 9 (2.4)
No identified exposure 365 (73.0) 27 (20.3) 339 (92.1)
Reported symptoms
Fever 281 (56.2) 54 (40.6) 227 (61.8) < 0.001
Cough 381 (76.2) 80 (60.1) 301 (82.0) < 0.001
Colds 142 (28.4) 51 (38.3) 91 (24.8) 0.003
Difficulty of breathing 185 (37.0) 18 (13.5) 167 (45.5) < 0.001
Headache 22 (4.4) 4 (3.0) 18 (4.9) 0.464
Malaise/fatigue 45 (9.0) 6 (4.5) 39 (10.6) 0.034
Diarrhoea 34 (6.8) 5 (3.8) 29 (7.9) 0.112
Anosmia 37 (7.4) 6 (4.5) 31 (8.4) 0.176
Ageusia 33 (6.6) 6 (4.5) 27 (7.4) 0.312
Loss of appetite 23 (4.6) 0 23 (6.3) 0.001
Co-morbidities
Hypertension 177 (35.4) 37 (27.8) 140 (38.1) 0.033
Diabetes 87 (17.4) 13 (9.8) 74 (20.2) 0.007
Bronchial asthma 22 (4.4) 7 (5.3) 15 (4.1) 0.622
HIV 6 (1.3) 0 6 (1.6) 0.349
Cardiac disease 20 (4.0) 3 (2.3) 17 (4.6) 0.306
Tuberculosis (any form) 41 (8.2) 4 (3.0) 37 (10.1) 0.009
At least one underlying disease 258 (51.6) 53 (40.0) 205 (55.9) 0.002
Clinical status
Asymptomatic 0 0 0 < 0.001
Mild 136 (27.2) 63 (47.4) 73 (19.9)
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cough (76.2%), fever (56.2%), and difficulty of breathing
(37.0%). Non-HCW were more likely to have symptoms
of fever (p < 0.001), cough (p < 0.001), difficulty of
breathing (p < 0.001), malaise or fatigue (p = 0.034), and
loss of appetite (p < 0.002), whereas HCW were more
likely to report coryzal symptoms (p = 0.003). All admit-
ted individuals had symptoms. HCW were more likely to
be classified as mild or moderate whereas non-HCW
were more likely to be severe or critical cases (p <
0.001). Twenty-nine (5.8%) individuals needed mechan-
ical ventilator support, all non-HCW. The median dur-
ation between the onset of symptoms to admission was
6 days (IQR 4–9 days), less for HCW compared with
non-HCW (5.5 days vs. 7 days; p < 0.001). The median
duration of hospital stay was 10 days (IQR 7–14 days)
with no difference between HCW and non-HCW. HCW
were more likely to be admitted within 14 days from the
symptom onset than non-HCW (96.9% vs. 87.8%; p <
0.016). Ct-values for the RT-PCR results were available
for 332 (66.4%) individuals. The majority of Ct-values
are within the range of 31–40 (67.9%) with no difference
between HCW and non-HCW. Additional diagnoses
were more common among non-HCW than among
HCW: pneumonia (49.3% vs. 16%; p < 0.001) and acute
respiratory distress syndrome (ARDS) (13.3% vs. 3%; p =
0.001). Among the 500 COVID-19-confirmed cases, 61
(12.2%) died. Mortality was higher among non-HCW
compared with HCW (16.3% vs. 0.7%; p < 0.001).
Table 2 shows the characteristics of the 367 non-
HCW by mortality. No death occurred for the 0–10
years age group, but deaths were recorded across all
other age groups. Compared to those who recovered,
individuals who died were more likely to be older (p <
0.001), male (p = 0.015), report difficulty of breathing (p
< 0.001), be HIV positive (p = 0.008), be intubated (p <
0.001), categorised as severe or critical (p < 0.001), have
a shorter mean hospital stay (p < 0.001), or have an al-
ternative diagnosis of pneumonia (p < 0.001) or ARDS
Table 1 Epidemiologic and clinical characteristics of healthcare and non-healthcare workers COVID-19 inpatients in San Lazaro
Hospital, January 2020 to October 2020 (Continued)
Characteristics Total (n = 500) HCW cases (n = 133) non-HCW (n = 367) p-value
Moderate 162 (32.4) 56 (42.1) 106 (28.9)
Severe 121 (24.2) 7 (5.3) 113 (31.1)
Critical 70 (14.0) 7 (5.3) 63 (17.2)
Intubated 29 (5.8) 0 29 (100.0) < 0.001
Duration between the onset of symptoms and admission
Mean (SD) 7 (13) 6 (3.5) 8 (15) < 0.001
Median (IQR) 6 (4–9) 5.5 (4–8) 7 (5–10)
0–14 days 448 (89.6) 126 (96.9) 322 (87.8) 0.016
15–30 days 39 (7.8) 4 (3.1) 35 (9.5)
> 30 days 6 (1.2) – 6 (1.6)
Hospitalisation days
Mean (SD) 12 (8) 11 (5) 12 (9) 0.340
Median (IQR) 10 (7–14) 10 (7–12) 10 (7–15)
Other diagnoses
Pneumonia 202 (40.4) 21 (16.0) 181 (49.3) < 0.001
Upper respiratory tract infection 24 (4.8) 9 (6.8) 15 (4.1) 0.238
Acute gastroenteritis 13 (2.6) 3 (2.3) 10 (2.7) 1.000
Acute respiratory distress syndrome 52 (10.4) 4 (3.0) 48 (13.1) 0.001
Ct-value distribution n = 105 N = 227 0.317
11–20 5 (1.5) 2 (1.9) 3 (1.3)
21–30 98 (30.0) 37 (35.2) 63 (27.7)
31–40 222 (67.9) 66 (62.9) 159 (70.0)
> 40 2 (0.6) – 2 (0.9)
Outcome
Died 61 (12.2) 1 (0.7) 60 (16.3) < 0.001
Discharged 439 (87.8) 132 (99.3) 307 (83.6)
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Table 2 Associations with mortality among 367 non-HCW COVID-19 inpatients in San Lazaro Hospital, January to October 2020
Characteristics All cases (n = 367) Died (n = 60) Discharged (n = 307) P-value
Age (years)
Mean (SD) 51 (18) 59 (20) 49 (17) < 0.001
Median (IQR) 53 (38–64) 65 (41–75) 51 (37–62)
Age group (years)
0–10 years old 7 (1.9) 0 7 (100.0) < 0.001
11–20 years old 9 (2.4) 2 (22.2) 7 (77.8)
21–40 years old 91 (24.8) 11 (12.1) 80 (87.9)
41–60 years old 137 (37.3) 14 (10.2) 123 (89.8)
61–80 years old 107 (29.2) 24 (22.4) 83 (77.6)
80+ years old 16 (4.4) 9 (56.2) 7 (43.8)
Sex
Female 158 (43.0) 17 (10.8) 141 (89.2) 0.015
Male 209 (57.0) 43 (20.6) 166 (79.4)
Nationality
Filipino 365 (99.5) 59 (16.6) 306 (83.8) 0.197
Chinese 2 (0.5) 1 (50.0) 1 (50.0)
Exposure history
International travel history within 14 days prior to admission 9 (2.5) 2 (22.2) 7 (77.8) 0.247
Exposed to a confirmed case 11 (3.0) 0 11 (100.0)
Risk of exposure in workplace 9 (2.5) 0 9 (100.0)
No identified exposure 338 (92.0) 58 (17.2) 280 (82.8)
Reported symptoms
Fever 227 (61.8) 39 (17.2) 188 (82.8) 0.583
Cough 301 (82.0) 53 (17.6) 248 (82.4) 0.200
Colds 91 (84.8) 9 (9.9) 82 (90.1) 0.071
Difficulty of breathing 167 (45.5) 48 (28.7) 119 (71.3) < 0.001
Headache 18 (4.9) 2 (11.1) 16 (88.9) 0.749
Malaise/fatigue 39 (10.6) 3 (7.7) 36 (92.3) 0.168
Diarrhoea 29 (7.9) 1 (3.5) 28 (96.5) 0.050
Anosmia 31 (8.4) 1 (3.2) 30 (96.7) 0.041
Ageusia 27 (7.4) 1 (3.7) 26 (96.3) 0.065
Loss of appetite 23 (6.3) 5 (21.7) 18 (78.3) 0.558
Co-morbidities
Hypertension 140 (38.1) 22 (15.7) 118 (84.3) 0.796
Diabetes 74 (20.2) 14 (18.9) 60 (81.1) 0.486
Bronchial asthma 15 (4.1) 0 15 (100.0) 0.145
HIV 6 (1.6) 4 (66.7) 2 (33.3) 0.008
Cardiac disease 17 (4.6) 3 (17.6) 14 (82.3) 0.747
Tuberculosis (any form) 37 (10.1) 10 (27.0) 27 (73.0) 0.097
At least one underlying disease 205 (55.8) 36 (17.6) 169 (82.4) 0.480
Clinical status
Asymptomatic 0 0 0 < 0.001
Mild 73 (19.9) 1 (1.4) 71 (98.6)
Moderate 106 (28.9) 0 104 (98.1)
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(p < 0.001). There were no significant associations in
mortality by nationality, exposure history, duration be-
tween onset of symptoms and admission, and Ct-value.
Conclusions
In this study, we describe the epidemiological and clinical
characteristics of the first 500 confirmed COVID-19 indi-
viduals admitted to an infectious disease referral hospital
in Metro Manila. There were significant differences in
characteristics, symptomatology, and outcomes between
healthcare and non-healthcare workers. This likely reflects
the changes in policy for admission and access to testing,
with many frontline healthcare workers with mild symp-
toms admitted to the hospital in the early days of the epi-
demic [13]. Non-healthcare workers were more likely to
report cough, fever, and difficulty of breathing and have
pneumonia and more severe disease [14, 15].
The mortality rate among non-HCW was 16.4%, com-
parable to the 17.5% mortality reported among the first
200 COVID-19 cases at the Philippine General Hospital
and a similar population in Indonesia with a mortality
rate of 12% [15, 16], but lower compared to those re-
ported in large cohorts in high-income countries [17,
18]. Older age was associated with mortality as consist-
ently reported elsewhere [14, 17, 18]. The presence of an
underlying illness among COVID-19 non-HCW (82.4%)
is similar to other case series reported in North America
(88%) [17] and the UK (77.5%) [18], but comorbidities of
diabetes and hypertension were not associated with mor-
tality in our study as would be expected [14, 19]. This
may reflect reporting biases or our limited sample size.
HIV positivity was significantly associated with mortality
(p = 0.008). As the tertiary referral hospital for infectious
diseases in the country, SLH preferentially caters to
complex cases of infectious diseases even before the pan-
demic started, such as HIV. Further investigation sug-
gested that these individuals included referrals from
other hospitals with medical problems in addition to
COVID-19.
Our analysis has some limitations. The retrospective
design of our study and reliance on the available data
from the CIF meant that some variables were incom-
plete. Details on the patients’ course in the wards and
treatment received were also not available. As data from
an infectious disease referral hospital, caution should be
considered in interpreting the results in the context of
Table 2 Associations with mortality among 367 non-HCW COVID-19 inpatients in San Lazaro Hospital, January to October 2020
(Continued)
Characteristics All cases (n = 367) Died (n = 60) Discharged (n = 307) P-value
Severe 114 (31.1) 23 (20.2) 89 (77.4)
Critical 63 (17.2) 36 (48.7) 38 (51.3)
Intubated 29 (7.9) 28 (96.5) 1 (3.5) < 0.001
Duration between the onset of symptoms and admission
Mean (SD) 8 (15) 5 (33) 8 (7) 0.229
Median (IQR) 7 (5–10) 6 (4–9) 7 (5–10)
0–14 days 322 (88.7) 53 (16.4) 269 (87.6) 0.047
15–30 days 35 (9.6) 4 (11.4) 31 (88.6)
> 30 days 6 (1.7) 3 (50.0) 3 (50.0)
Hospitalisation days
Mean (SD) 12 (9) 7 (9) 13 (9) < 0.001
Median (IQR) 10 (7–15) 5 (1–10) 11 (8–16)
Other diagnoses
Pneumonia 181 (49.3) 49 (27.1) 132 (72.9) <0.001
Upper respiratory tract infection 15 (4.1) 0 15 (100.0) 0.080
Acute gastroenteritis 10 (2.7) 0 10 (100.0) 0.378
Acute respiratory distress syndrome 48 (13.1) 33 (68.7) 15 (31.2) <0.001
Ct-values distribution N = 227 N = 36 N = 191
11–20 3 (1.3) 1 (33.3) 2 (66.70) 0.178
21–30 63 (27.7) 14 (22.2) 49 (77.8)
31–40 159 (70.0) 20 (12.6) 139 (87.4)
> 40 2 (0.9) 1 (50.0) 1 (50.0)
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the general population. In conclusion, we report various
sociodemographic and clinical characteristics associated
with increased COVID-19 mortality among hospitalised
individuals in Metro Manila, Philippines. Our results
support the country’s national guideline on COVID-19
vaccination which prioritises healthcare workers, the eld-
erly population, and people with comorbidities and im-
munodeficiency states.
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